Characterization and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement

CompletedOBSERVATIONAL
Enrollment

340

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
High-surgical Risk Patients with Severe Tricuspid Regurgitation
Interventions
PROCEDURE

transcatheter tricuspid valve replacement

The LuX-valve was implanted under fluoroscopic and echocardiographic guidance via the transjugular vein approach. Once the delivery system was introduced, it was adjusted within the right heart chamber to be perpendicular to the tricuspid annulus. The anterior leaflet was grasped using two leaflet graspers, and the ventricular portion of the device component was gradually released. After deploying the atrial disc to ensure the elimination of TR, septal anchoring was performed, and the delivery system was subsequently withdrawn.

Trial Locations (8)

100011

Beijing Anzhen Hospital, Beijing

100037

Fuwai Hospital, Beijing

200032

Zhongshan Hospital, Shanghai

200080

Shanghai General Hospital, Shanghai

361102

Xiamen Cardiovascular Hospital, Xiamen

430040

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

610041

West China Hospital, Chengdu

710032

Department of Cardiovascular Surgery, Xijing Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER